Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...
Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the ...
Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback